Early Treatment with Anti-VLA-4 mAb Can Prevent the Infiltration and/or Development of Pathogenic CD11b(+)CD4(+) T Cells in the CNS during Progressive EAE

Natalizumab is a humanized monoclonal antibody against the leukocyte adhesion molecule very late antigen (VLA)-4, and is currently an approved therapy for patients with relapsing-remitting multiple sclerosis (RRMS). However, it is unknown whether natalizumab is beneficial for progressive forms of MS...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Mindur, John E., Ito, Naoko, Dhib-Jalbut, Suhayl, Ito, Kouichi
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2014
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4045930/
https://ncbi.nlm.nih.gov/pubmed/24896098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0099068
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky